Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Beebe

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|April 14, 2025
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateSpencer I Danto, Mikhail Salganik, Anindita Banerjee, et al.
The British Journal of Dermatology|March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group studyMegan N Landis, Stacy R Smith, Gabriel Berstein, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2020
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateMichael F Robinson, Nemanja Damjanov, Bojana Stamenkovic, et al.
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Xenotransplantation|August 3, 2007
Production of homozygous alpha-1,3-galactosyltransferase knockout pigs by breeding and somatic cell nuclear transferMark B Nottle, Luke F S Beebe, Sharon J Harrison, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 17, 2023
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled TrialPhilip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|April 2, 2021
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With AbrocitinibEric L Simpson, Andreas Wollenberg, Robert Bissonnette, et al.
The Journal of Pain|June 28, 2017
Evidence for a Role of Nerve Injury in Painful Intervertebral Disc Degeneration: A Cross-Sectional Proteomic Analysis of Human Cerebrospinal FluidTony K Y Lim, Kathleen M Anderson, Pawan Hari, et al.
Nature Materials|January 22, 2019
Sterile particle-induced inflammation is mediated by macrophages releasing IL-33 through a Bruton's tyrosine kinase-dependent pathwayPankaj K Mishra, Mark Palma, Bonnie Buechel, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2003
Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activityMichael J Munchhof, Jean S Beebe, Jeffery M Casavant, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Arthritis & Rheumatology (Hoboken, N.J.)|April 14, 2025
Efficacy and Safety of Zimlovisertib, Ritlecitinib, and Tofacitinib, Alone and in Combination, in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateSpencer I Danto, Mikhail Salganik, Anindita Banerjee, et al.
The British Journal of Dermatology|March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group studyMegan N Landis, Stacy R Smith, Gabriel Berstein, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2020
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to MethotrexateMichael F Robinson, Nemanja Damjanov, Bojana Stamenkovic, et al.
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Xenotransplantation|August 3, 2007
Production of homozygous alpha-1,3-galactosyltransferase knockout pigs by breeding and somatic cell nuclear transferMark B Nottle, Luke F S Beebe, Sharon J Harrison, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 17, 2023
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled TrialPhilip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|April 2, 2021
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With AbrocitinibEric L Simpson, Andreas Wollenberg, Robert Bissonnette, et al.
The Journal of Pain|June 28, 2017
Evidence for a Role of Nerve Injury in Painful Intervertebral Disc Degeneration: A Cross-Sectional Proteomic Analysis of Human Cerebrospinal FluidTony K Y Lim, Kathleen M Anderson, Pawan Hari, et al.
Nature Materials|January 22, 2019
Sterile particle-induced inflammation is mediated by macrophages releasing IL-33 through a Bruton's tyrosine kinase-dependent pathwayPankaj K Mishra, Mark Palma, Bonnie Buechel, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2003
Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activityMichael J Munchhof, Jean S Beebe, Jeffery M Casavant, et al.
Pageof 15